Cypherpunk Technologies Inc. (CYPH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cypherpunk Technologies Inc. stock (CYPH) is currently trading at $0.74. Cypherpunk Technologies Inc. PE ratio is 10.07. Cypherpunk Technologies Inc. PS ratio (Price-to-Sales) is 160.10. WallStSmart rates CYPH as Sell.
- CYPH PE ratio analysis and historical PE chart
- CYPH PS ratio (Price-to-Sales) history and trend
- CYPH intrinsic value — DCF, Graham Number, EPV models
- CYPH stock price prediction 2025 2026 2027 2028 2029 2030
- CYPH fair value vs current price
- CYPH insider transactions and insider buying
- Is CYPH undervalued or overvalued?
- Cypherpunk Technologies Inc. financial analysis — revenue, earnings, cash flow
- CYPH Piotroski F-Score and Altman Z-Score
- CYPH analyst price target and Smart Rating
Cypherpunk Technologies Inc.
📊 No data available
Try selecting a different time range
CYPH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Cypherpunk Technologies Inc. (CYPH)
CYPH trades 29% above its Graham fair value of $0.48, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Cypherpunk Technologies Inc. (CYPH) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Cypherpunk Technologies Inc. (CYPH) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Cypherpunk Technologies Inc. (CYPH) Areas to Watch (4)
Very expensive at 160.1x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low profitability relative to shareholder equity
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Cypherpunk Technologies Inc. (CYPH) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.41) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Price/Sales, Market Cap, Return on Equity. Some valuation metrics including Price/Sales (160.10) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 5.11%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 5.11% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Sales and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CYPH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CYPH's Price-to-Sales ratio of 160.10x trades 197% above its historical average of 53.96x (91th percentile), historically expensive. The current valuation is 0% below its historical high of 160.1x set in Feb 2026, and 1901% above its historical low of 8x in Jul 2021. Over the past 12 months, the PS ratio has expanded from ~12.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cypherpunk Technologies Inc. (CYPH) · FINANCIAL SERVICES › ASSET MANAGEMENT
The Big Picture
Cypherpunk Technologies Inc. operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor ASSET MANAGEMENT industry trends, competitive moves, and regulatory changes that could impact Cypherpunk Technologies Inc..
Bottom Line
Cypherpunk Technologies Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:50:07 AM
About Cypherpunk Technologies Inc.(CYPH)
NASDAQ
FINANCIAL SERVICES
ASSET MANAGEMENT
USA
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.